FDA approves Victrelis for hepatitis C

 
 
Share this
 
 

The safety and effectiveness of Victrelis was evaluated in two phase 3 clinical trials with 1,500 adult patients. In both trials, two-thirds of patients receiving Victrelis in combination with pegylated interferon and ribavirin experienced a significantly increased sustained virologic response (i.e., the hepatitis C virus was no longer detected in the blood 24 weeks after stopping treatment), compared to pegylated interferon and ribavirin alone, the current standard of care. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm255390.htm